Business Wire

NY-QUARTILE

13.12.2021 19:02:04 CET | Business Wire | Press release

Share
Quartile Acquires Sidecar to Form Largest Cross-Channel E-Commerce Advertising Platform

Quartile , the leading ad optimization platform for top e-commerce marketplace sellers, today announced it has acquired Sidecar , a performance marketing technology provider for e-commerce retailers and brands that works across all major advertising platforms , including Google, Microsoft Bing, Facebook, Instagram, and Amazon.

The two companies will combine under the Quartile name, growing the brand into the world’s largest cross-channel e-commerce advertising platform. Both platforms apply machine-learning and natural-language processing to provide data-driven strategies and best practices to brand marketers while also offering best-in-class reporting and ad management.

Quartile expects the acquisition to double its amount of advertising spend under management across all platforms to $2 billion in 2021. Unilever, Burt’s Bees and Thrasio are among the more than 5,000 brands currently using the platforms on e-commerce channels like Amazon, Google, Instacart, Walmart, Facebook and Shopify. The combined company will have clients across 26 countries.

"By combining Sidecar's best-in-class solution and expertise managing campaigns for DTC e-commerce merchants with our proprietary AI-driven analytics and optimization platform, we will create the most comprehensive and powerful e-commerce suite," said Daniel Knijnik, co-founder and CEO at Quartile. “The two companies’ complementary businesses, products and relationships will offer unrivaled benefits for our combined customers, employees and other stakeholders across a diverse set of markets.”

"Retail marketers and small businesses are up against great odds when it comes to being seen in online marketplaces. Only 0.1% of products account for around 80% of the sales on e-commerce marketplaces, so brands recognize they need a holistic solution to help them compete in all marketplaces and direct-to-consumer websites,” added Knijnik.

Both Quartile and Sidecar have witnessed exponential growth in recent years as fiercer competition among e-commerce merchants has led to increased advertising spend. Amazon is predicted to grow its ad revenue to $24.47 billion by the end of 2021, an increase of 55.5% year over year, closing the gap as the world's third-largest ad network after Google and Facebook (whose ad revenues grew 34% and 43% , respectively). The platforms provide e-commerce marketers with a critical edge in this fast growing industry.

"We share a passion with the Quartile team for helping small businesses and large retailers grow their exposure, shopping audience, and brands across channels," said Andre Golsorkhi, founder and CEO of Sidecar. "This acquisition is the ultimate example of how we continue to dig in for our customers as their challenges become more complex. By combining the aptitudes and technologies of Sidecar and Quartile, we are continuing to ensure the performance marketing excellence that retailers rely on us for.”

Terms of the acquisition were not disclosed. The combined businesses will comprise a team of more than 300 personnel. Rockbridge Growth Equity, a Detroit-based private equity firm which originally invested a minority stake in Quartile in September of last year, will remain the lead institutional investor in the transaction. Existing Sidecar shareholders will also own a significant stake of the post-acquisition Quartile entity. Investment Bank Canaccord Genuity served as the exclusive financial advisor to Quartile and Rockbridge in connection with the transaction.

“We are thrilled to be partnering with the Sidecar team,” said Kevin Prokop, founder and managing partner at Rockbridge. “The Sidecar team has built an exceptional business. We believe the combination of Quartile and Sidecar creates a distinctive company that is uniquely positioned to capture the exciting opportunities in the e-commerce marketing industry.”

About Quartile:

Founded in 2016, Quartile is an artificial intelligence and machine learning-powered ad optimization platform for leading e-commerce marketplace sellers, such as Amazon, Walmart.com, and Instacart. Quartile’s advertising technology uses proprietary technology and six patented algorithms to make real-time decisions based on accurate data for improved performance and growth. The Quartile platform is an easy-to-use dashboard that equips sellers with the tools to manage their retail media in every marketplace, enabling them to optimize campaigns at the product level to maximize sales, lower the advertising cost of sale (ACoS), and improve margins. For more information visit: www.quartile.com .

About Sidecar:

Sidecar offers performance marketing excellence to retailers and brands. Sidecar’s advanced technology and proprietary data, combined with years of performance marketing expertise, help its customers unlock the full potential of today’s most powerful search, shopping, social, and marketplace channels. For more information, visit: getsidecar.com

Link:

ClickThru

Social Media:

https://www.facebook.com/quartiledigital

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye